Pfizer closes $635M vaccines purchase from Baxter

Pfizer has completed its $635 million purchase from Baxter International Inc. of two vaccines and part of the factory in Orth, Austria, where they're made.

It's part of Pfizer Inc.'s strategy for building a vaccine portfolio.

The vaccines include one against the common group C strain of meningitis, a bacterial brain infection that can kill rapidly and spread easily through respiratory and throat secretions.

The other protects against tick-borne encephalitis, a viral brain infection. It sickens thousands in Europe and Asia each year and is becoming more common.

New York-based Pfizer sells the Prevnar vaccine against pneumonia, ear infections and other diseases, which brings in more than $4 billion per year. It recently got approval for its meningitis B vaccine and is developing vaccines against Staphylococcus aureus and C. difficile.


Explore further

FDA approves vaccine to block meningitis strain (Update)

© 2014 The Associated Press. All rights reserved.

Citation: Pfizer closes $635M vaccines purchase from Baxter (2014, December 1) retrieved 31 March 2020 from https://medicalxpress.com/news/2014-12-pfizer-635m-vaccines-baxter.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments